| Nov 4 |
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
|
| Nov 4 |
CureVac to Present at the 12th International mRNA Health Conference
|
| Oct 30 |
US Penny Stocks To Watch In October 2024
|
| Oct 30 |
GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness
|
| Oct 28 |
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
|
| Oct 8 |
CureVac: Back To Square One
|
| Oct 8 |
Pfizer, BioNTech win lawsuit against CureVac over COVID vaccine patents in U.K.
|
| Oct 8 |
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
|
| Oct 1 |
CureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firms
|
| Sep 13 |
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
|
